Smoking Cessation and Nicotine De-Addiction Market to Reach US$ 27.84 Bn by 2031: TMR Study

MarketBusiness
Jul.19.2022
Massive adoption of nicotine replacement therapy (NRT) products propelling sales of products in smoking cessation and nicotine de-addiction market; demand for OTC smoking cessation products high

Wilmington, Delaware, United States, July 18, 2022 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - Analysis of smoking cessation industry statistics over the past few decades has found that rise in use of prescription as well as OTC products to help smokers quit smoking, which mainly include skin patches and gums. The smoking cessation and nicotine de-addiction market is projected to reach US$ 27.84 Bn in 2031. The target population is becoming aware of the health burden of cigarette smoking in that smoking-related diseases cause premature deaths every year.
 

Innovative marketing campaign for the availability and effectiveness of various smoking cessation products have bolstered their awareness of smoking cessation benefits, thus expanding the canvas for companies in the smoking cessation and nicotine de-addiction market. National research agencies in the U.S. and the U.K. are massively supporting tobacco-related disease research. As a result of these factors and market trends, smoking cessation programs have grown notably in Europe, expanding the smoking cessation market size.

A spate of studies have underscored the effectiveness of e-cigarettes in smoking cessation therapy, which has broadened the horizon in smoking cessation and nicotine de-addiction market. The number of young adults and adolescents who are serious about quitting smoking has increased significantly over the years. This has expanded profitable avenues for commercializing gum, lozenges, inhalers, nasal sprays, and nicotine patches. Awareness of smoking cessation products through online channels is also increasing among the target population, thus catalyzing growth of smoking cessation and nicotine de-addiction market.
 

Get PDF Brochure for More Insights - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1849

Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands said it will phase out its myblu vaping business in the United States, citing prolonged FDA approval timelines for new vape products. The company said it will instead focus on modern oral nicotine products in the U.S., including the expansion of its Zone brand and new flavors. While overall next-generation product revenue continued to grow, revenue from the category in the Americas declined sharply.
May.12
FDA Tobacco Center Pushes Review-Efficiency Statement After Commissioner’s Exit
FDA Tobacco Center Pushes Review-Efficiency Statement After Commissioner’s Exit
FDA CTP issued a May 7 statement on accelerating product review and improving PMTA efficiency, but did not push it via official X and newsletter until May 13, one day after FDA Commissioner Marty Makary’s resignation was confirmed. FDA has not explained the delay, and no public evidence links it directly to the leadership change. The timing is notable given CTP’s usual 24-hour distribution practice.
Special Report
May.14
Italy Fines PMI €7 Million Over Misleading ‘Smoke-Free Future’ Marketing Claims
Italy Fines PMI €7 Million Over Misleading ‘Smoke-Free Future’ Marketing Claims
Italy’s Competition and Market Authority (AGCM) has fined Philip Morris Italia €7 million, finding that the company’s use of “smoke-free future” and related claims in promoting products such as IQOS, VEEV and ZYN could mislead consumers.
Jun.16
Reuters: Big Tobacco Emerges as Winner After FDA Regulatory Shift
Reuters: Big Tobacco Emerges as Winner After FDA Regulatory Shift
According to Reuters, major tobacco companies may emerge as key beneficiaries after the U.S. FDA loosened regulations on vaping and nicotine pouch products, a shift that has sparked debate over public health risks.
Industry Insight
May.26
PMI Highlights 43 Million Smoke-Free Users at Stockholm Summit
PMI Highlights 43 Million Smoke-Free Users at Stockholm Summit
Philip Morris International says about 43 million adults worldwide now use its smoke-free products, with nearly 70% having stopped using cigarettes and smoke-free products accounting for about 43% of its net revenues.
Jun.18
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13